Nerve Damage

Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

Retrieved on: 
Sunday, January 8, 2023
Well, Severe cognitive impairment, SAD, Autoimmune disease, Complement component 1q, Autoimmune hemolytic anemia, Disease, Growth, LN, Plasma, Medicine, Neurodegeneration, Investment, The First Half of My Life, GA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, HIV disease progression rates, Lupus nephritis, HD, Nephritis, AFL, Physician, Eye, Pivotal trial, FDA, Autoimmunity, Geographic atrophy, GBS, Anemia, Food, ALS, Continuous Progress Mathematics, Time-invariant system, Therapy, Webcast, Nerve, Hemolysis, CAD, MAD, Multifocal motor neuropathy, Cold agglutinin disease, Nerve Damage, Patient, Ophthalmology, MMN, Conference, Pharmaceutical industry, Waiha, Amyotrophic lateral sclerosis

BRISBANE, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today reported progress across its broad portfolio of complement therapies and outlined its focus on four flagship programs to support its advancement to a late-stage biopharmaceutical company developing first-in-class treatments for complement-mediated diseases of the body, brain and eye.

Key Points: 
  • Annexon has prioritized resources and execution of late-stage development of its four flagship programs: Guillain-Barré syndrome (GBS), Huntington’s disease (HD), geographic atrophy (GA) and its first-in-kind oral small molecule, ANX1502.
  • Our mission is to free the body, brain and eye from diseases driven by the classical complement cascade,” said Douglas Love, president and CEO of Annexon.
  • Following an assessment of the market opportunity in wAIHA and a range of additional autoimmune indications, Annexon has determined not to advance development in wAIHA.
  • A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

Retrieved on: 
Thursday, January 5, 2023
Bupivacaine, Calendar, Betamethasone, Pain, Pharmacokinetics, Telephone, Ataxia–telangiectasia, PK, Neuropathic pain, TSX, ACST, Trial of the century, Nerve Damage, A-T, Safety, FDA, Human, Pharmaceutical industry, Internet service provider, Postherpetic neuralgia

ET to review the recently reported preliminary topline results from two separate Phase 1 pharmacokinetic (PK) studies for GTX-101 and GTX-102.

Key Points: 
  • ET to review the recently reported preliminary topline results from two separate Phase 1 pharmacokinetic (PK) studies for GTX-101 and GTX-102.
  • Both studies successfully met all target outcome measures.
  • The conference call will be available via telephone by dialing toll free 844-836-8745 for U.S. callers or +1 412-317-6797 for international callers.
  • On December 28, 2022, Acasti announced that the preliminary topline results of the pharmacokinetic (PK) bridging study for GTX-102 met all primary outcome measures.

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

Retrieved on: 
Thursday, December 22, 2022
Standard of care, Bupivacaine, Calendar, Betamethasone, Pain, Blood, Pharmacokinetics, Gabapentin, Lidocaine, PHN, Ataxia–telangiectasia, PK, Neuropathic pain, Hydrogen chloride, TSX, Tmax, ACST, Skin, NDA, Toxicity, Risk, Trial of the century, Irritation, Nerve Damage, Patient, Plasma, Type, A-T, AUC, Safety, Physician, FDA, Headache, Human, Hypoesthesia, Postherpetic neuralgia, Cmax, Pharmaceutical industry, Risk management, Generic drug

The final clinical study report is anticipated to be received by the Company in the first half of 2023.

Key Points: 
  • The final clinical study report is anticipated to be received by the Company in the first half of 2023.
  • The potential benefits of GTX-101 could include faster onset of action and a longer duration of pain relief as compared to the lidocaine patch.
  • The study enrolled 48 healthy adult subjects (24 males/24 females, mean age = 36 years), in 12 subjects per cohort.
  • Following GTX-101 topical application: headache (3%) and numbness (3%) at the sprayed area, and
    In conclusion, this Single Dose PK study was conducted successfully, and it achieved all its primary outcome measures.

20 GUNSHOT VICTIMS - MOSTLY FEDERAL AGENTS, MILITARY VETERANS, AND POLICE OFFICERS - WOUNDED BY THEIR DEFECTIVE SIG SAUER P320 PISTOLS, FILE AN UNPRECEDENTED LAWSUIT AGAINST THE GUNMAKER

Retrieved on: 
Thursday, December 1, 2022
Milwaukee, Nerve Damage, History, P320, Firearm, Distress, Sig, Veteran, Special operations, SIG Sauer P320, MPD, File, Armendáriz, United States Army, Army, Bleeding, SMB, Park, Plaintiff, Trauma center, Freedom, Woman, Milwaukee Police Department, Safety, Gunsmith, Private investigator, Tobacco, SIG Sauer

CONCORD, N.H., Dec. 1, 2022 /PRNewswire/ -- Highly-trained local, state and federal law enforcement officers, as well as experienced military veterans, are among 20 victims wounded by their "dangerously defective" Sig Sauer P320 pistols who just filed an unprecedented lawsuit against the maker of the controversial firearm as a result of their guns firing uncommanded, according to Saltz Mongeluzzi & Bendesky P.C.,  attorneys for the victims. The filing (Armendariz et. al. v. Sig Sauer, Inc. USDC, New Hampshire No.1:22-cv-00536) is the latest, and by far largest P320 lawsuit against Sig Sauer on behalf of injured victims;  filed late yesterday, it details each unintended, un-commanded firing and wounding of the users, and the life-altering consequences. The documented incidents occurred across more than one dozen states.

Key Points: 
  • We intend to prove that the Sig Sauer P320 is without question the most dangerous pistol on the market in the United States."
  • SMB now represents more than 50 victims injured by Sig Sauer's P320 pistol that features a spring-loaded striker firing mechanism.
  • SMB expects to file additional suits in the coming days on behalf of more injured victims.
  • Besides a copy of the newly-filed lawsuit, additional related information on the Sig Sauer litigation and the gun's troubled history - can be found at www.smbb.com/SigSauer .

Global Diabetic Neuropathy Market Report 2022: Cutting-Edge Product Development to Shape Sector Moving Forward - ResearchAndMarkets.com

Retrieved on: 
Friday, November 11, 2022
Diabetes, Pharmaceutical, Health, People, Exercise, Industry, Chief executive officer, Pharmacy, Alternative, MEA, Primary, VPS, Incidence, Diabetic neuropathy, Market share, Nerve Damage, Autonomic neuropathy, Peripheral neuropathy, Obesity, Analysis, Moyamoya disease, Hyperglycemia, USD, Food and Drug Administration, CAGR, Distribution, Diabetes, Talc, Growth, Marketing, Hospital, Medical device, Pharmaceutical industry, Food, Disorder

The "Global Diabetic Neuropathy Market, By Disorder, By Distribution Channel & By Region- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Diabetic Neuropathy Market, By Disorder, By Distribution Channel & By Region- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Neuropathy Market and to estimate the size of various other dependent submarkets.
  • Based on disorder the market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy.
  • Based on region the global Diabetic Neuropathy market is segmented into North America, Europe, Asia-Pacific, Latin America, and MEA.

Acasti Pharma to Present at Q4 Investor Summit

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Marketing, PHN, Skull, FDA, Risk, Private Securities Litigation Reform Act, Bleeding, Securities Act of 1933, Nerve Damage, Postherpetic neuralgia, SEC, NASDAQ, Brain, Summit, Compliance, Securities Exchange Act of 1934, Company, ACST, Disability, Assam Global Investors' Summit, Neuropathic pain, Subarachnoid hemorrhage, SubArachnoid Space, CEO, TSX, A-T, SAH, Pharmaceutical industry, Security (finance), Ataxia–telangiectasia

LAVAL, Qubec, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that Jan DAlvise, President and CEO of Acasti Pharma will be presenting virtually at the Q4 Investor Summit.

Key Points: 
  • LAVAL, Qubec, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that Jan DAlvise, President and CEO of Acasti Pharma will be presenting virtually at the Q4 Investor Summit.
  • Investors interested in participating in one-on-one meetings should contact Acasti Investor Relations at [email protected] , or their Investor Summit representatives.
  • Acasti is a specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases.
  • Acasti undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

Retrieved on: 
Monday, November 7, 2022
GLOBE, Marketing, PHN, Skull, FDA, Risk, Telephone, Private Securities Litigation Reform Act, Bleeding, Securities Act of 1933, Nerve Damage, Postherpetic neuralgia, SEC, NASDAQ, Brain, Compliance, Securities Exchange Act of 1934, ACST, Disability, Neuropathic pain, Subarachnoid hemorrhage, SubArachnoid Space, TSX, A-T, SAH, Pharmaceutical industry, Internet service provider, Ataxia–telangiectasia

A webcast of the call may be accessed at https://app.webinar.net/KP8QXdZzj5R or on the Companys Investor Relations section of the website: https://www.acastipharma.com/investors/ .

Key Points: 
  • A webcast of the call may be accessed at https://app.webinar.net/KP8QXdZzj5R or on the Companys Investor Relations section of the website: https://www.acastipharma.com/investors/ .
  • A webcast replay will be available on the Companys Investors News/Events section of the website ( https://www.acastipharma.com/investors/ ) through November 14, 2023.
  • Acasti is a specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases.
  • Acasti undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Defender Offers Five Valuable Tips to Stay a Step Ahead of Diabetic Foot Ulcers

Retrieved on: 
Tuesday, November 8, 2022
Brooks Sports, Diabetes, Foot, Sensation, Patient, Compliance, Amputation, Death, Diabetic foot ulcer, Pressure, Ulcer, Life, Nerve Damage, Irritation, Blister, DPN, DFU, Quality of life, Risk, Pharmaceutical industry, Meat, Shoemaking, Health insurance, Defender

MIAMI, Nov. 8, 2022 /PRNewswire/ -- In honor of National Diabetes Month, Defender, a next-generation designer and manufacturer of innovative foot care solutions, shares valuable guidance to help mitigate diabetic foot ulcers and prevent potential risk of amputation. Approximately 37.3 million1 Americans live with diabetes and one in four of those individuals will develop a foot ulcer or open sore2. Recognizing these wounds must be taken very seriously—and that an estimated 15 to 20 percent of people with foot ulcers will experience an amputation3—Dr. Jason Hanft, seasoned podiatrist with 30+ years of experience in lower extremity medicine and surgery, limb salvage and wound care, points out that many amputations can be avoided with proper footwear.

Key Points: 
  • Recognizing these wounds must be taken very seriouslyand that an estimated 15 to 20 percent of people with foot ulcers will experience an amputation3Dr.
  • Foot Defender alleviates average contact pressure across the foot by up to 50% as compared to other protective boots on the market.
  • To help provide support for people with diabetic foot ulcers, the company is offering 20 percent off the entire month of November on FootDefender.com .
  • Defender is a leading designer and manufacturer of innovative foot care solutions that are changing the game for people with complex foot care issues, from heel pain to diabetic foot ulcers.

1 in 2 diabetics suffer from Peripheral Neuropathy[1] during their lifetime

Retrieved on: 
Tuesday, November 8, 2022
Paresthesia, Shoulder, Health professional, Pantene, Miracle Mineral Supplement, P&G, Ageing, Head & Shoulders, World Diabetes Day, DPN, International Diabetes Federation, Pain, Quality of life, Awareness, Risk, IDF, Neuropathic pain, Senior, Nerve Damage, Psyllium, Diabetes, Gillette, Education, Burning Sensations, Health, Digestive, Prickle (protein), Patient, Mortality, Vitamin, Omeprazole, Prevalence, Pregnancy, Vicks, PN, Physician, Febreze, Disease, Pharmacist, Mineral, Oral hygiene, Hypoesthesia, Phosphorus, Pharmaceutical industry, Dietary supplement, Tide, Crest, Pampers, Whispering, Peripheral neuropathy, B vitamins

Launched on World Diabetes Day across 18 countries, the campaign raises awareness on Peripheral Neuropathy in diabetes, and the importance of early identification and timely treatment.

Key Points: 
  • Launched on World Diabetes Day across 18 countries, the campaign raises awareness on Peripheral Neuropathy in diabetes, and the importance of early identification and timely treatment.
  • With Diabetes Mellitus being the leading cause[2] of Peripheral Neuropathy (PN), the increasing prevalence of PN is closely linked to the rise in the number of diabetic patients.
  • Symptoms of peripheral neuropathy include numbness, tingling, prickling, and burning sensations in the hands and feet.
  • Besides diabetes mellitus, B vitamins deficiencies and aging are other high-risk factors leading to peripheral nerve damage.

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022

Retrieved on: 
Saturday, November 5, 2022
American Heart Association, Private Securities Litigation Reform Act, Form 10-K, Adult, Intellia Therapeutics, NYHA, Part Two, U.S. Securities and Exchange Commission, Clinical trial, TTR, NTLA, Form, CRISPR, Cardiomyopathy, SEC, Polyneuropathy, Heart failure, Protein, Regeneron Pharmaceuticals, GLOBE, Amyloid, Cas9, Familial amyloid polyneuropathy, Security (finance), Degenerative disease, Nerve Damage, Patient, Cancer, Nobel Prize, Human, Science, Heart, Cardiology, Amyloidosis, Physician, ATTR, Genome, Observation, AHA, Annual report, Therapy, III, Serum, Tissue, Safety, New York Heart Association Functional Classification, NASDAQ, Risk, Liver, Pharmaceutical industry, Vaccine

Results were presented in a Late-Breaking Science oral presentation at the American Heart Association (AHA) Scientific Sessions 2022, held November 5 7 in Chicago, Illinois.

Key Points: 
  • Results were presented in a Late-Breaking Science oral presentation at the American Heart Association (AHA) Scientific Sessions 2022, held November 5 7 in Chicago, Illinois.
  • The interim data from the dose-escalation portion of the Phase 1 study include 12 adult patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I III heart failure.
  • These data highlight NTLA-2001s potential as a one-time treatment to permanently inactivate the TTR gene and reduce the disease-causing protein in people with ATTR-CM.
  • We believe a single dose of NTLA-2001 has the potential to halt and potentially reverse this life-threatening disease.